A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades is a research paper published in Stats (2020). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA188480-01A1
National Institutes of Health
Grant: 1U01CA232859-01
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials
National Institutes of Health
Grant: 2P01CA098912-11
Core B: Pathology and High-resolution Imaging Core
National Institutes of Health
Grant: 1P01 CA233452-01
National Center for Advancing Translational Sciences
Grant: L1 TR001881-01
NCI NIH HHS
Grant: P01 CA098912
NCATS NIH HHS
Grant: UL1 TR001881
NCI NIH HHS
Grant: P01 CA233452
NCI NIH HHS
Grant: R01 CA188480
NCI NIH HHS
Grant: U01 CA232859
National Institutes of Health
Grant: 5P01CA233452-02
Determinants of Liver Metastasis
National Institutes of Health
Grant: 3UL1TR001881-01S2
UCLA Clinical Translational Science Institute
National Institutes of Health
Grant: 1R01CA188480-01A1
Design of Cancer Phase I/II Clinical Trials Using Drug Combinations of Cytotoxic and Biologic Agents
Fields of Study
Keywords
Sustainable Development Goals